AUM Biosciences Further Strengthens Board of Directors with Addition of Dr. Matt Devalaraja

AUM Biosciences (AUM), a Singapore-based company officially announced today the addition of Dr. Matt Devalaraja to its Board of Directors. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.

aum-doc

About Matt Devalaraja

Matt Devalaraja is the founder, Chief Scientific Officer and Head of Research and Development of Corvidia Therapeutics. Dr. Devalaraja is an immunologist with more than 20 years of experience in drug discovery and development across multiple therapeutic areas.

Prior to founding Corvidia, Dr. Devalaraja was Director of Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for Corvidia spinout. He also was Head of Immunology Research, Pharmacokinetics and Toxicology groups at Human Genome Sciences, and was integral to the approval of Benlysta for Lupus and Raxibacumab for Anthrax.

Dr. Devalaraja started his career at Pfizer in Ann Arbor and brought forth the first biologic program for Pfizer's Global Immunology portfolio. As Head of Biologics Discovery at Pfizer Ann Arbor, he initiated multiple programs across various therapeutic areas, including immunology and cardiovascular space, many of which are currently in various stages of clinical development. Currently, he is on the board of P2D Biosciences and is a founder of multiple startup biotech companies. Dr. Devalaraja received his Ph.D. from the University of Kentucky and completed his Post-Doctoral training at Vanderbilt University.

In June 2020, Corvidia Therapeutics was acquired by Novo Nordisk for a total deal value of 2.1 Billion USD.

“Dr. Devalaraja is a highly accomplished scientist and entrepreneur with an outstanding track record in bringing new drugs to market. We are delighted to have him join our Board and look forward to his guiding AUM’s growth” stated. Vishal Doshi, Chairman of the Board, AUM Biosciences.

“I look forward to working with and guiding AUM as they build their drug development pipeline and increase their global footprint in the oncology space” stated Dr. Matt Devalaraja.

About AUM Biosciences

AUM Biosciences is an award-winning, oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.

The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR). AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation. For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award. For more information, please visit www.aumbiosciences.com www.aumbiosciences.com or info@aumbiosciences.com